Send me real-time posts from this site at my email

Here's Why AnaptysBio Shares Are Slipping Today

What happened

Shares of AnaptysBio (NASDAQ: ANAB), a clinical-stage biotechnology company, fell in response to the imminent departure of Dominic Piscitelli, the company's CFO since 2017. Investors were worried that Piscitelli's resignation announcement signaled trouble for the company's lead candidate etokimab and pounded the stock 13.6% lower on Tuesday.

So what

Over the past couple of years, AnaptysBio has shifted the focus for etokimab, a potential first-in-class IL-33 inhibitor, away from peanut allergy prevention and toward the treatment of eczema, chronic sinusitis, and asthma. Shifting focus isn't necessarily bad but it doesn't inspire confidence, either. In June, AnaptysBio shares fell after Regeneron (NASDAQ: REGN) announced disappointing results from a clinical trial with another IL-33 inhibitor.

Image source: Getty Images.

As a pre-commercial company, AnaptysBio needs to get a new drug application into the hands of the Food and Drug Administration (FDA) as soon as possible. Following signals that don't bode well for etokimab's future, the abrupt departure of a CFO ahead of some important readouts has been taken as a sign of trouble.

Now what

There are two midstage clinical trials with etokimab scheduled to read out before the end of the year. Investors should realize that right now, independent data monitors are the only people who know which patients received etokimab and which were given placebos. That means Piscitelli shouldn't have any more knowledge about etokimab's upcoming results than the rest of us.

While the abrupt departure of an executive at this pivotal time is somewhat troubling, odds are that Piscitelli's simply reacting to another job offer. If investors are looking for potential signs of trouble with etokimab, increasing activity around AnaptysBio's less advanced pipeline is probably a more accurate signal.

10 stocks we like better than AnaptysBio
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AnaptysBio wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 1, 2019

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends AnaptysBio. The Motley Fool has a disclosure policy.


Popular posts

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue